STTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Shattuck Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$5.37−0.05 (-0.92%)
Close on Oct 19, 2026
- Market cap
- $696.91M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
83.5%
84M of 100M shares
Institutional holders
100
37 new, 20 sold out
Net institutional buying
28M
In Q2 2026
Insider trades, 12 months
1 buys · 6 sales
Net sold $341.85K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Redmile Group, LLC | 9,819,084 | 9.90% | 13D (active) amendment | Jun 9, 2026 |
| Orbimed Advisors LLC | 9,021,127 | 9.99% | 13D (active) amendment | Jun 11, 2026 |
| Prosight Management, LP | 6,543,240 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Deep Track Capital, LP | 5,000,033 | 5.17% | 13G (passive) | Jun 10, 2026 |
| Phillip Gross | 4,675,000 | 9.79% | 13G (passive) amendment | Dec 31, 2024 |
| T. Rowe Price Investment Management, Inc. | 13,432,540 | 15.30% | 13G (passive) amendment | Jun 30, 2026 |
| Jeremy C. Green | 10,019,421 | 9.90% | 13D (active) amendment | Jul 15, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of STTK | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13,432,540 | 13.38% | $93.22K | +3,566,982 | 0.06% |
| Adage Capital Partners Gp, L.L.C. | 8,122,179 | 8.09% | $56.37M | +3,477,222 | 0.08% |
| Redmile Group, LLC | 6,892,033 | 6.87% | $47.83M | +1,352,309 | 3.21% |
| Orbimed Advisors LLC | 6,306,127 | 6.28% | $43.76M | – | 0.81% |
| Prosight Management, LP | 5,957,877 | 5.94% | $41.35M | +953,438 | 7.12% |
| BlackRock, Inc. | 3,935,810 | 3.92% | $27.31M | +3,425,004 | 0.00% |
| Frazier Life Sciences Management, L.P. | 3,750,000 | 3.74% | $26.03M | New | 0.57% |
| NEXTBio Capital Management LP | 3,727,348 | 3.71% | $25.87M | +577,441 | 11.90% |
| Deep Track Capital, LP | 3,706,734 | 3.69% | $25.72M | New | 0.37% |
| Vanguard Capital Management LLC | 3,207,865 | 3.20% | $22.26M | +930,689 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 2,641,076 | 2.63% | $18.33K | +858,288 | 0.00% |
| Pinnacle Associates Ltd | 1,871,442 | 1.86% | $12.99M | +503,219 | 0.14% |
| Wellington Management Group Llp | 1,767,938 | 1.76% | $12.27M | New | 0.00% |
| Geode Capital Management, LLC | 1,584,756 | 1.58% | $11.00M | +939,051 | 0.00% |
| Clark Estates Inc/Ny | 1,430,167 | 1.42% | $9.93M | −45,481 | 2.29% |
| abrdn plc | 1,405,851 | 1.40% | $9.76M | +246,530 | 0.01% |
| Point72 Asset Management, L.P. | 1,170,732 | 1.17% | $8.12M | +139,683 | 0.01% |
| 683 Capital Management, LLC | 1,157,216 | 1.15% | $8.03M | +357,216 | 0.39% |
| State Street Corp | 1,026,394 | 1.02% | $7.12M | +762,626 | 0.00% |
| Boxer Capital Management, LLC | 1,000,000 | 1.00% | $6.94M | New | 0.52% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 100 | 84M | 83.5% | 37 / 36 | 15 / 20 | 33M | 5M |
| Q1 2026 | 84 | 56M | 55.9% | 24 / 33 | 14 / 4 | 20M | 4M |
| Q4 2025 | 65 | 43M | 42.4% | 17 / 17 | 14 / 4 | 11M | 4M |
| Q3 2025 | 56 | 36M | 36.3% | 14 / 11 | 23 / 18 | 11M | 3M |
| Q2 2025 | 61 | 29M | 28.6% | 11 / 20 | 20 / 25 | 2M | 4M |
| Q1 2025 | 75 | 31M | 31.1% | 9 / 16 | 24 / 7 | 1M | 1M |
| Q4 2024 | 75 | 32M | 31.5% | 13 / 26 | 19 / 16 | 6M | 10M |
| Q3 2024 | 78 | 36M | 36.2% | 15 / 29 | 18 / 9 | 5M | 1M |
| Q2 2024 | 74 | 34M | 34.1% | 23 / 28 | 17 / 18 | 6M | 4M |
| Q1 2024 | 70 | 32M | 31.6% | 26 / 25 | 10 / 13 | 5M | 3M |
| Q4 2023 | 57 | 29M | 29.1% | 25 / 14 | 10 / 8 | 10M | 0M |
| Q3 2023 | 41 | 20M | 19.8% | 1 / 6 | 19 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of STTK | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Value Fund, Inc. | 3,565,344 | 3.55% | $24.74M | 0.23% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3,114,735 | 3.10% | $21.62M | 0.23% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,366,616 | 2.36% | $16.42M | 0.00% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,986,099 | 1.98% | $13.78M | 0.12% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 1,677,742 | 1.67% | $11.64M | 0.23% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,538,564 | 1.53% | $10.68M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 768,222 | 0.77% | $5.33M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 671,918 | 0.67% | $4.75M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 501,709 | 0.50% | $3.48M | 0.02% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 391,662 | 0.39% | $2.33M | 0.04% | May 31, 2026 |
| Vanguard Explorer Fund | 319,591 | 0.32% | $2.26M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 284,317 | 0.28% | $1.69M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 206,111 | 0.21% | $1.43M | 0.09% | Jun 30, 2026 |
| Small Cap Value Portfolio | 203,628 | 0.20% | $1.41M | 0.21% | Jun 30, 2026 |
| North Square Dynamic Small Cap Fund | 200,532 | 0.20% | $1.19M | 0.15% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Taylor Schreiber | Chief Executive Officer, Director | 2,732,972 | 2.72% | May 13, 2026 |
| Abhinav A. Shukla | Chief Technical Officer | 98,533 | 0.10% | Jul 7, 2026 |
| Arundathy N. Pandite | Chief Medical Officer | 136,219 | 0.14% | Jul 2, 2026 |
| Stephen Stout | See Remarks | 93,366 | 0.09% | May 18, 2026 |
| Andrew R. Neill | Chief Financial Officer | 292,251 | 0.29% | May 14, 2026 |
| Casi DeYoung | Chief Business Officer | 73,480 | 0.07% | Jan 27, 2026 |
| Genesis GP LLC OrbiMed | Director | 1,051,021 | 1.05% | Jun 15, 2026 |
| Advisors Llc Orbimed | Director | 5,255,106 | 5.24% | Jun 15, 2026 |
| Mona Ashiya | Director | 5,255,106 | 5.24% | Jun 15, 2026 |
| Capital GP IX LLC OrbiMed | Director | 1,051,021 | 1.05% | Jun 15, 2026 |
| Clay B. Siegall | Director | 318,608 | 0.32% | Jun 11, 2026 |
| Helen M. Boudreau | Director | – | – | Jun 2, 2026 |
| George Golumbeski | Director | 54,613 | 0.05% | Jun 2, 2026 |
| Daniel G. Baker | Director | – | – | Jun 2, 2026 |
| Neil W. Gibson | Director | 52,745 | 0.05% | Jun 2, 2026 |
| Jeremy Green | Director, 10% owner | 5,406,353 | 5.39% | Aug 26, 2025 |
| Redmile Group, LLC | Director, 10% owner | 5,615,489 | 5.60% | Aug 26, 2025 |
| Tyler Brous | Director | 238,088 | 0.24% | Jul 16, 2025 |
| Carrie Brownstein | Director | – | – | Jul 16, 2025 |
| Michael Stewart Lee | Director | – | – | Jul 16, 2025 |
| Amy Kate Sasser | Director | – | – | Jul 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Abhinav A. Shukla Chief Technical Officer | Jul 6, 2026 | Option exercise | +12,153 | $3.57 | $43.39K | 98,533 |
| Abhinav A. Shukla Chief Technical Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −410 | $7.01 | $2.87K | 86,380 |
| Abhinav A. Shukla Chief Technical Officer | Jul 2, 2026 | Option exercise | +410 | $3.57 | $1.46K | 86,790 |
| Abhinav A. Shukla Chief Technical Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −100 | $7.07 | $707 | 86,380 |
| Abhinav A. Shukla Chief Technical Officer | Jul 1, 2026 | Option exercise | +100 | $3.57 | $357 | 86,480 |
| Arundathy N. Pandite Chief Medical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −30,000 | $7.01 | $210.30K | 136,219 |
| Abhinav A. Shukla Chief Technical Officer | Jun 30, 2026 | Sale(10b5-1 plan) | −23,365 | $7.08 | $165.42K | 86,380 |
| Abhinav A. Shukla Chief Technical Officer | Jun 30, 2026 | Option exercise | +23,365 | $3.57 | $83.41K | 109,745 |
| Clay B. Siegall Director | Jun 9, 2026 | Buy | +62,500 | $4.00 | $250.00K | 318,608 |
| Clay B. Siegall Director | May 22, 2026 | Award | +128,054 | $1.08 | $138.30K | 256,108 |
| Abhinav A. Shukla Chief Technical Officer | May 21, 2026 | Award | +5,122 | $1.08 | $5.53K | 86,380 |
| Stephen Stout See Remarks | May 15, 2026 | Award | +12,805 | $1.08 | $13.83K | 93,366 |
| Abhinav A. Shukla Chief Technical Officer | May 12, 2026 | Option exercise | +2,032 | $3.57 | $7.25K | 83,290 |
| Abhinav A. Shukla Chief Technical Officer | May 12, 2026 | Sale(10b5-1 plan) | −2,032 | $7.01 | $14.24K | 81,258 |
| Andrew R. Neill Chief Financial Officer | May 12, 2026 | Award | +64,027 | $1.08 | $69.15K | 292,251 |
| Arundathy N. Pandite Chief Medical Officer | May 12, 2026 | Sale(10b5-1 plan) | −30,000 | $6.61 | $198.30K | 166,219 |
| Taylor Schreiber Chief Executive Officer, Director | May 12, 2026 | Award | +25,610 | $1.08 | $27.66K | 122,222 |
| Stephen Stout See Remarks | May 10, 2026 | Tax withholding | −968 | $6.85 | $6.63K | 80,561 |
| Casi DeYoung Chief Business Officer | Jan 25, 2026 | Tax withholding | −2,286 | $4.15 | $9.49K | 73,480 |
| Andrew R. Neill Chief Financial Officer | Jan 25, 2026 | Tax withholding | −2,589 | $4.15 | $10.74K | 228,224 |
| Stephen Stout See Remarks | Jan 25, 2026 | Tax withholding | −593 | $4.15 | $2.46K | 81,529 |
| Arundathy N. Pandite Chief Medical Officer | Jan 25, 2026 | Tax withholding | −3,195 | $4.15 | $13.26K | 196,219 |
| Arundathy N. Pandite Chief Medical Officer | Jan 10, 2026 | Tax withholding | −6,851 | $4.75 | $32.54K | 199,414 |
| Casi DeYoung Chief Business Officer | Jan 10, 2026 | Tax withholding | −5,699 | $4.75 | $27.07K | 75,766 |
| Andrew R. Neill Chief Financial Officer | Jan 10, 2026 | Tax withholding | −6,660 | $4.75 | $31.64K | 230,813 |
| Stephen Stout See Remarks | Jan 10, 2026 | Tax withholding | −4,153 | $4.75 | $19.73K | 82,122 |
| Mona Ashiya Director | Aug 25, 2025 | Buy | +5,255,106 | $0.87 | $4.57M | 5,255,106 |
| Mona Ashiya Director | Aug 25, 2025 | Buy | +1,051,021 | $0.87 | $914.39K | 1,051,021 |
| Capital GP IX LLC OrbiMed Director | Aug 25, 2025 | Buy | +1,051,021 | $0.87 | $914.39K | 1,051,021 |
| Capital GP IX LLC OrbiMed Director | Aug 25, 2025 | Buy | +5,255,106 | $0.87 | $4.57M | 5,255,106 |
| Abhinav A. Shukla Chief Technical Officer | Aug 25, 2025 | Award | +5,122 | $0.87 | $4.46K | 81,258 |
| Andrew R. Neill Chief Financial Officer | Aug 25, 2025 | Award | +64,027 | $0.87 | $55.70K | 237,473 |
| Clay B. Siegall Director | Aug 25, 2025 | Award | +128,054 | $0.87 | $111.41K | 128,054 |
| Taylor Schreiber Chief Executive Officer, Director | Aug 25, 2025 | Award | +25,610 | $0.87 | $22.28K | 96,612 |
| Stephen Stout See Remarks | Aug 25, 2025 | Award | +12,805 | $0.87 | $11.14K | 86,275 |
| Abhinav A. Shukla Chief Technical Officer | Jan 25, 2025 | Tax withholding | −2,261 | $1.16 | $2.62K | 73,536 |
| Arundathy N. Pandite Chief Medical Officer | Jan 25, 2025 | Tax withholding | −3,211 | $1.16 | $3.72K | 206,265 |
| Casi DeYoung Chief Business Officer | Jan 25, 2025 | Tax withholding | −2,297 | $1.16 | $2.66K | 81,465 |
| Abhinav A. Shukla Chief Technical Officer | Jan 10, 2025 | Tax withholding | −4,830 | $1.19 | $5.75K | 74,597 |
| Casi DeYoung Chief Business Officer | Jan 10, 2025 | Tax withholding | −5,727 | $1.19 | $6.82K | 83,762 |
| Arundathy N. Pandite Chief Medical Officer | Jan 10, 2025 | Tax withholding | −6,884 | $1.19 | $8.19K | 209,476 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Sale | −133,371 | $1.25 | $166.71K | 5,406,353 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Other | +1,026,888 | $1.25 | $1.28M | 5,539,724 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Other | −1,026,888 | $1.25 | $1.28M | 4,512,836 |
| Jeremy Green Director, 10% owner | Dec 4, 2024 | Buy | +133,371 | $1.25 | $166.71K | 5,539,724 |
| Taylor Schreiber Chief Executive Officer, Director | Oct 7, 2024 | Buy | +36,500 | $1.21 | $44.17K | 71,002 |
| Tyler Brous Director | Jun 28, 2024 | Buy | +3,000 | $3.90 | $11.70K | 238,088 |
| Tyler Brous Director | Jun 27, 2024 | Buy | +5,416 | $3.89 | $21.07K | 235,088 |
| Taylor Schreiber Chief Executive Officer, Director | Jun 26, 2024 | Buy | +14,400 | $3.47 | $49.97K | 34,502 |
| Taylor Schreiber Chief Executive Officer, Director | Jun 4, 2024 | Option exercise | +3,050 | $3.57 | $10.89K | 20,102 |
| Stephen Stout See Remarks | May 10, 2024 | Tax withholding | −967 | $10.42 | $10.08K | 73,470 |
| Redmile Group, LLC Director, 10% owner | Mar 28, 2024 | Other | −4,425 | – | – | 5,615,489 |
| Stephen Stout See Remarks | Mar 6, 2024 | Option exercise | +6,459 | $3.57 | $23.06K | 85,791 |
| Stephen Stout See Remarks | Mar 6, 2024 | Sale(10b5-1 plan) | −6,459 | $10.53 | $68.01K | 79,332 |
| Stephen Stout See Remarks | Mar 6, 2024 | Sale(10b5-1 plan) | −4,895 | $10.53 | $51.54K | 74,437 |
| Stephen Stout See Remarks | Mar 6, 2024 | Sale(10b5-1 plan) | −4,650 | $10.53 | $48.96K | 79,332 |
| Stephen Stout See Remarks | Mar 6, 2024 | Option exercise | +4,650 | $3.51 | $16.32K | 83,982 |
| Arundathy N. Pandite Chief Medical Officer | Jan 30, 2024 | Tax withholding | −2,920 | $9.99 | $29.17K | 216,360 |
| Stephen Stout See Remarks | Jan 30, 2024 | Tax withholding | −593 | $9.99 | $5.92K | 79,332 |
| Casi DeYoung Chief Business Officer | Jan 30, 2024 | Tax withholding | −2,008 | $9.99 | $20.06K | 89,489 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Abhinav A. Shukla Officer | Jul 2, 2026 | 410 | $2.87K | Jul 2, 2026 | Stock Option Exercise |
| Abhinav A. Shukla Officer | Jul 1, 2026 | 100 | $707 | Jul 1, 2026 | Stock Option Exercise |
| Abhinav A. Shukla Officer | Jun 30, 2026 | 23,365 | $165.47K | Jun 30, 2026 | Stock Option Exercise |
| Pandite Arunthathy Officer | May 12, 2026 | 60,000 | $421.20K | May 12, 2026 | Restricted Stock Awards |
| Abhinav A. Shukla Officer | May 12, 2026 | 2,032 | $14.24K | May 12, 2026 | Option Granted - 01/25/2023 |
| Redmile Group, LLC Director, 10% Stockholder | Dec 4, 2024 | 133,371 | $150.71K | Dec 4, 2024 | Open Market Purchases or Purchases in Public Offering |
| Charles Stout Stephen Officer | Mar 6, 2024 | 16,004 | $168.52K | Mar 6, 2024 | Restricted Stock |
| Andrew R. Neill Officer | Jan 10, 2024 | 25,000 | $250.00K | Jan 10, 2024 | Option Exercise |